Intellia’s Adel Nada Joins Casebia as Chief Medical Officer

Casebia Therapeutics has appointed Adel Nada to serve as its chief medical officer. He comes to Cambridge, MA-based Casebia from Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]), where he was vice president and head of clinical development. Formed in 2016, Casebia is a joint venture between Bayer and CRISPR Therapeutics (NASDAQ: [[ticker:CRSP]]) that is using CRISPR/Cas9 gene-editing to develop treatments for genetic disorders.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.